PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors (PRECARDIA)

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This is a multicentre European double-blind,randomized and controlled trial with 2 parallel groups (1 study medication, 1 placebo) in order to analyse the impact of ACE inhibitors (ACEi) in subjects who carry a mutation but have not yet developed DCM (dilated cardiomyopathy).

Objective of the trial: Study the impact of ACE inhibitors (ACEi) in subjects who carry a mutation (leading to a genetic form of heart failure) but have not yet developed DCM.

Context. Dilated Cardiomyopathy (DCM) is one of the leading causes of Heart Failure due to systolic dysfunction and at least 30% of DCM are of familial/genetic origin, usually with autosomal dominant inheritance, and underlying genes and mutations are increasingly identified. Familial Dilated Cardiomyopathy (fDCM) is characterized by age-related penetrance (or delayed-onset), that means that the cardiac expression of the disease (echocardiographic abnormalities) is usually absent for a long period and progressively appears with advanced age, usually after 20 years of age

Hypothesis : ACEi may delay or prevent the occurrence of DCM in these subjects (pre-clinical stage).

Expected results: If the hypothesis is confirmed, and as a consequence, the knowledge derived from basic research (genes identification in DCM) will be translated into clinical practice (early identification of subjects at high risk of developing heart failure through predictive genetic testing) with the development of new therapeutic management (early ACEi) that will help to decrease the morbidity and mortality associated with the disease. This will constitute a paradigm of the development of preventive medicine thanks to the development of genetics in the cardiovascular field.

Subjects who are concerned are ≥18 years of age and ≤60 years, carry a mutation responsible for DCM and are at a preclinical stage of the disease. Total duration of treatment (perindopril versus placebo) is 3 years. A total number of 200 participants will be enrolled (100 in each group) in 7 centres.

Condition or disease	Intervention/treatment	Phase
Dilated Cardiomyopathy	Drug: perindopril; Drug: placebo	Phase 3

Detailed Description:

This study is part of a broader research program, "INHERITANCE" (INtegrated HEart Research In TrANslational genetics of dilated Cardiomyopathies in Europe) research project, submitted to EU (FP7 European Union, HEALTH-2009-2.4.2-3: Translation of basic knowledge on inherited cardiomyopathies into clinical practice) and accepted in 2009 (Grant agreement n° 241924, global coordinator: Pr Eloisa Arbustini, Pavia, Italy).

• Precardia / clinical trial Principal Investigator: Dr Philippe Charron, Pitié Salpêtrière hospital, France
• FP7 Global Inheritance network coordinator: Pr Eloisa Arbustini, Italia

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	6 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Triple (Participant, Care Provider, Investigator)
Primary Purpose:	Treatment
Official Title:	Preventive Effect of ACE Inhibitor Perindopril)on the Onset or Progression of Left Ventricular Dysfoction in Subjects at a Preclinical Stage From Families With Dilated Cardiomyopathy
Study Start Date :	December 2011
Actual Primary Completion Date :	January 2014
Actual Study Completion Date :	January 2014

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: perindopril	Drug: perindopril; form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).; Other Name: Coversyl
Placebo Comparator: placebo; same form, administration, posology, frequency and duration as perindopril	Drug: placebo; form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Change in left ventricle diameter / volume / ejection fraction [ Time Frame: baseline,12 months, 24 months and 36 months after inclusion ]

   Primary composite end point:

   • Occurence of DCM (LV ejection fraction LVEF<45% and LVEDD>112%)
   • or deterioration of LV end-diastolic diameter / volume (occurrence of events defined as "+4% LVEDD/LVEDV")
   • or deterioration of Ejection fraction (occurrence of events defined as "-4% LVEF")

   All criteria determined either by Echocardiography (primary end-point 1) or by Magnetic resonance imaging (MRI) primary end-point 2).

Secondary Outcome Measures :

1. Echocardiographic deterioration of LVEDD or Ejection fraction [ Time Frame: at baseline and at 24 months and 36 months after inclusion ]
   Echocardiographic deterioration of LVEDD (comparison of average "final LVEDD compared to baseline LVEDD" between arms) or Ejection fraction (comparison of average "final LVEF vs baseline LVEF" between arms)
2. MRI - deterioration of LVEDVol or Ejection fraction [ Time Frame: at baseline and at 36 months after inclusion ]
   MRI deterioration of LVEDVol (comparison of average "final LVEDVol compared to baseline LVEDVol" between arms) or Ejection fraction (comparison of average "final LVEF vs baseline LVEF" between arms)
3. Occurence of DCM (Echo: EF< 45% and LVEDD>112%, ref Mahon, 2005) [ Time Frame: baseline, 12 months, 24 months and 36 months after inclusion ]
   Occurence of DCM on Echocardiography: EF< 45% and LVEDD>112% (ref Mahon, 2005)
4. Deterioration of other Echocardiographic parameters [ Time Frame: at baseline, at 12 months, 24 months and 36 months after inclusion ]

   Deterioration of other Echocardiographic parameters:

   • TDI velocities (average Sa & Ea velocities) at the mitral annulus (lateral and septal), and the E/Ea ratio
   • strain and strain rate (radial, longitudinal, circonferential strain rate in the basal, mid and apical segments)
   • LV volumes (LVED Vol and LVES Vol, Simpson method, 4 cavity incidence)
5. Deterioration of hormonal biomarkers in serum [ Time Frame: at baseline, at 18 months and 36 months after inclusion ]

   Deterioration of hormonal biomarkers in serum:

   • Natriuretic peptid: BNP and NTproBNP (+/-4% or final versus baseline).
   • Mid-Regional pro-Adrenomedullin (MR-proADM) and Mid-Regional proANP, (+/-4% or final versus baseline).
6. Clinical end-point [ Time Frame: at each visit (inclusion, at 2 weeks, 3 months, 6 months, then every 6 months to 36 months after inclusion) ]

   Clinical end-point (statistical power is known to be sufficient):

   • Symptoms: Dyspnoea (NYHA stage 1 to 4)
   • Hospitalisation (not planed) for heart failure
7. Clinical end-point: death [ Time Frame: at each visit (inclusion, at 2 weeks, 3 months, 6 months, then every 6 months to 36 months after inclusion) ]

   Clinical end-point (statistical power is known to be sufficient):

   • All cause death
   • cardiovascular death (Safety end-point: no excess of)

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 60 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Age: ≥18 years and ≤60 years
• At least one family member should have a clinical diagnosis of dilated cardiomyopathy (LVEF<45% and LVEDD>112%)and should not be considered as the burn-out phase of another cardiomyopathy (such as HCM, ARVC). LV noncompaction may co-exist with DCM in this patient.NB:in a patient with a mutation in LMNA gene, LVEDD may be normal whereas EF is markedly reduced, so that only a reduced LVEF is mandatory(LVEF<45%).
• Carriers of the mutation that has been identified in the family as associated with DCM, and who have received appropriate genetic counselling before and after the announcement of the genetic result. The mutation within the family should be considered as disease-causing.
• No obvious DCM as assessed by diagnostic criteria indicated elsewhere on echocardiography (WHO & Mestroni et al. 1999 and Mahon et al. 2005: references 3 and 9): LVEF <45% and enlarged LVEDD (>112% of predicted value according to age,BSA).

• Presence of minor LV abnormality:

  • isolated LVEDD > 112% (Henry Formula)
  • or reduced systolic dysfunction: 45% < LVEF < 55%, as assessed on echocardiography.
• Able to provide informed consent, and signed informed consent.
• Able to understand and accept the study constraints
• For some European countries (such as France and Spain): participants (by themselves) should have medical health care coverage to be included in a research study

Exclusion Criteria:

• Other disease or factor that can cause minor LV abnormalities, such as cardiotoxic treatment or significant blood hypertension (with uncontrolled blood pressure or significant hypertrophy on echocardiography).
• Contraindication to ACE inhibitor
• Participants who are already treated with ACE inhibitor, sartan or aldosterone receptor antagonists (for various reason such as arterial hypertension) can not be included in this study, unless they have been off these drugs for a period of 6 weeks before inclusion.
• Impaired renal function: estimated Glomerular Filtration Rate (eGFR), using MDRD formula, < 60 ml/mn/1.73m2.
• Baseline serum potassium >5.5 mmol/L.
• Pregnant, parturient or breastfeeding woman or woman of childbearing potential not under effective contraception or planned pregnancy.
• Participation in another therapeutic trial in the previous 3 months
• Participants treated with lithium
• Participant under legal guardianship

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

Denmark
Skejby University Hospital SUH, Aarhus Universit Hospital
Aarhus, Denmark, 8200
France
Pitié Salpêtrière Hospital
Paris, France, 75013
Germany
University of Heidelberg UKLHD
Heidelberg, Germany, 69120
Italy
Academic Hospital IRCCS Foundation Policlinico San Matteo (OSM)
Pavia, Italy, 27100
Netherlands
Academisch Medisch Centrum AMC and InterUniversity Institute AMC/ICIN
Amsterdam, Netherlands, 1105 AZ
Spain
Health in Code SL (SME) - Hospital Marítimo de Oza.
A Coruña, Spain, 15006
United Kingdom
The Heart Hospital, University College London NHS Foundation Trust
London, United Kingdom, W1G 8PH

Sponsors and Collaborators

Institut National de la Santé Et de la Recherche Médicale, France

Investigators

Principal Investigator:	PHILIPPE CHARRON	PITIE SALPETRIERE HOSPITAL, PARIS, FRANCE

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier:	NCT01583114 History of Changes
Other Study ID Numbers:	C10-44; 2010-023184-18 ( EudraCT Number )
First Posted:	April 23, 2012
Last Update Posted:	February 24, 2016
Last Verified:	February 2016

Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France:

dilated cardiomyopathy; heart failure; genetics	mutation carrier; ACE treatment; preclinical

Additional relevant MeSH terms:

Cardiomyopathies; Cardiomyopathy, Dilated; Heart Diseases; Cardiovascular Diseases; Cardiomegaly; Angiotensin-Converting Enzyme Inhibitors	Perindopril; Protease Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents